Table 1.
Patient and tumor characteristics according to bisphosphonate use.
| Non-Bisphosphonate (N=1410) | Bisphosphonate (N=39) | ||||
|---|---|---|---|---|---|
| N | (%) | N | (%) | P | |
|
| |||||
| Age (median) | 49 | 58 | |||
|
| |||||
| Age | |||||
| < 50 | 726 | (51.5) | 2 | (5.1) | |
| ≥ 50 | 684 | (48.5) | 37 | (94.9) | < 0.001 |
|
| |||||
| Menopausal Status | |||||
| Pre | 674 | (47.9) | 6 | (15.4) | |
| Post | 733 | (52.1) | 33 | (84.6) | < 0.001 |
|
| |||||
| Body Mass Index | |||||
| Normal/underweight | 454 | (33.3) | 18 | (47.4) | |
| Overweight | 439 | (32.2) | 14 | (36.8) | |
| Obese | 472 | (34.6) | 6 | (15.8) | 0.04 |
|
| |||||
| Race | |||||
| White/other | 1202 | (85.2) | 37 | (94.9) | |
| Black | 208 | (14.8) | 2 | (5.1) | 0.09 |
|
| |||||
| Clinical Stage | |||||
| I | 56 | (4.0) | 2 | (5.1) | |
| II | 759 | (54.0) | 27 | (69.2) | |
| III | 590 | (42.0) | 10 | (25.6) | 0.12 |
|
| |||||
| Nuclear Grade | |||||
| I | 50 | (3.7) | 1 | (2.6) | |
| II | 443 | (32.4) | 18 | (47.4) | |
| III | 876 | (64.0) | 19 | (50.0) | 0.15 |
|
| |||||
| LVI | |||||
| Negative | 932 | (68.5) | 30 | (78.9) | |
| Positive | 428 | (31.5) | 8 | (21.1) | 0.17 |
|
| |||||
| Tumor subtype | |||||
| Hormone receptor + | 767 | (55.1) | 24 | (61.5) | |
| Her2neu + | 250 | (17.9) | 8 | (20.5) | |
| Triple negative | 376 | (27.0) | 7 | (17.9) | 0.45 |